Ozempic May Lower Risk of Kidney and Heart Events in High-Risk Patients

Photo byPhoto by Diabetesmagazijn.nl on Unsplash

Scientists are interested in the expanding use of Ozempic as its benefits extend beyond its original role as a diabetes treatment. Recent findings highlight its potential advantages for heart and kidney health, particularly in patients with type 2 diabetes and chronic kidney disease.

A major international trial funded by Novo Nordisk involved over 3,500 participants from 28 countries, focusing on the effects of semaglutide, the active ingredient in Ozempic. Administered at a lower-than-usual dose for diabetes treatment, participants received weekly injections of semaglutide or a placebo. Results showed that those on semaglutide experienced slower kidney function decline, reduced risk of kidney failure, lower systolic blood pressure, and modest weight loss compared to the placebo group.

Over 3.4 years, participants on Ozempic had a 24% lower risk of significant kidney events, an 18% lower risk of cardiovascular events like heart attacks, and a 20% lower risk of death from any cause. This suggests significant potential for Ozempic to protect kidneys, hearts, and overall health in high-risk populations.

The shift from diabetes treatment to kidney disease management aligns well, considering that type 2 diabetes is a leading cause of chronic kidney disease globally. While financial incentives exist for drug manufacturers like Novo Nordisk, the therapeutic potential of Ozempic in kidney health is supported by its ability to control blood glucose levels and potentially reduce inflammation and oxidative stress in kidney cells.

GLP-1 receptor agonists like semaglutide, which mimic a natural hormone to improve blood sugar control and suppress appetite, are showing promise not just in diabetes management but also in mitigating cardiovascular and kidney risks. However, the exact mechanisms behind these benefits remain unclear and require further investigation.

Current guidelines are already suggesting the consideration of GLP-1 receptor agonists for diabetic kidney disease due to limited treatment options. Future research aims to determine whether these medications could benefit broader populations with chronic kidney disease beyond those with diabetes, further expanding their therapeutic potential.